XML 71 R54.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2024 | Aug. 31, 2024 | May 29, 2024 | Mar. 31, 2024 | Dec. 31, 2023
--- | --- | --- | --- | --- | ---
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | $ 198,587 |  |  |  | $ 70,364
Allowance | (3,538) |  |  |  | (8,073)
Net carrying value | 195,049 |  |  |  | 62,291
Financial royalty liability current | 10,000 |  |  |  |
Qarziba |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 105,329 |  |  |  | 0
Allowance | (484) |  |  |  | 0
Net carrying value | 104,845 |  |  |  | 0
Agenus (Bot/Bal) |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 40,815 |  |  |  | 0
Allowance | (408) |  |  |  | 0
Net carrying value | 40,407 |  | $ 75,000 |  | 0
Tolerance Therapeutics (Tzield) |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 25,613 |  |  |  | 25,810
Allowance | (101) |  |  |  | (101)
Net carrying value | 25,512 |  |  |  | 25,709
Ensifentrine inventors |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 15,969 | $ 13,600 |  | $ 3,800 | 0
Allowance | (157) |  |  |  | 0
Net carrying value | 15,812 |  |  |  | 0
Elutia (CorMatrix) |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 9,418 |  |  |  | 13,304
Allowance | (2,268) |  |  |  | (7,490)
Net carrying value | 7,150 |  |  |  | 5,814
InvIOs |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 1,238 |  |  |  | 0
Allowance | (62) |  |  |  | 0
Net carrying value | 1,176 |  |  |  | 0
Selexis |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 205 |  |  |  | 940
Allowance | (58) |  |  |  | (179)
Net carrying value | 147 |  |  |  | 761
Ovid (Soticlestat) |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |
Gross carrying value | 0 |  |  |  | 30,310
Allowance | 0 |  |  |  | (303)
Net carrying value | $ 0 |  |  |  | $ 30,007

X
- Definition Financial Royalty Assets, Allowance + References No definition available. + Details
Name: | lgnd_FinancialRoyaltyAssetsAllowance
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Financial Royalty Assets, Gross + References No definition available. + Details
Name: | lgnd_FinancialRoyaltyAssetsGross
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Financial Royalty Assets, Net + References No definition available. + Details
Name: | lgnd_FinancialRoyaltyAssetsNet
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Financial Royalty Assets, Net Current + References No definition available. + Details
Name: | lgnd_FinancialRoyaltyAssetsNetCurrent
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_QARZIBAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_AgenusInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_EnsifentrineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_InvIOsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_SelexisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |